A systems view of epithelial-mesenchymal transition signaling states

Clinical and Experimental Metastasis

Volumn 28, Issue 2, 2011, Pages 137-155

  Thomson, Stuart ^a   Petti, Filippo ^a   Sujka Kwok, Izabela ^a   Mercado, Peter ^a   Bean, James ^a   Monaghan, Melissa ^a   Seymour, Sean L ^a   Argast, Gretchen M ^a   Epstein, David M ^a   Haley, John D ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

Cell polarity; Drug resistance; EMT; Epithelial mesenchymal transition; Kinase; Non small cell lung cancer; Phosphorylation; Snail; Systems biology; TGF beta; Zeb1

Indexed keywords

SOMATOMEDIN C RECEPTOR; VASCULOTROPIN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HOMEODOMAIN PROTEIN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ARTICLE; CANCER INVASION; CELL JUNCTION; CELL POLARITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; METASTASIS; PROTEIN PHOSPHORYLATION; TUMOR CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; LUNG NON SMALL CELL CANCER; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HOMEODOMAIN PROTEINS; HUMANS; PHOSPHORYLATION; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 79953303497     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9367-3     Document Type: Article

References (105)

1. Thiery JP et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890
2. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 14(6):818-829 (Pubitemid 351757205)
3. Hill R et al (2005) Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123(6):1001-1011 (Pubitemid 41785416)
4. Zeisberg EM et al (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67(21):10123-10128 (Pubitemid 350070783)
5. Orimo A et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3):335-348 (Pubitemid 40692295)
6. Gupta GP, Massague J (2006) Cancer metastasis: Building a framework. Cell 127(4):679-695 (Pubitemid 44781029)
7. Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119-150
8. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401
9. Dohadwala M et al (2006) Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 66(10):5338-5345 (Pubitemid 43844959)
10. Condeelis J, Pollard JW (2006) Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2):263-266 (Pubitemid 43121975)
11. Patsialou A et al (2009) Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 69(24): 9498-9506
12. Vega S et al (2004) Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18(10):1131-1143 (Pubitemid 38669034)
13. Grunert S, Jechlinger M, Beug H (2003) Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4(8):657-665 (Pubitemid 36934968)
14. Yamaguchi H, Wyckoff J, Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17(5):559-564 (Pubitemid 41267171)
15. Prasad M, Montell DJ (2007) Cellular and molecular mechanisms of border cell migration analyzed using time-lapse livecell imaging. Dev Cell 12(6):997-1005 (Pubitemid 46805918)
16. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442-454
17. Tsuji T, Ibaragi S, Hu GF (2009) Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69(18):7135-7139
18. Damonte P et al (2007) EMT tumorigenesis in the mouse mammary gland. Lab Invest 87(12):1218-1226 (Pubitemid 350126707)
19. Blaukovitsch M et al (2006) Sarcomatoid carcinomas of the lung-are these histogenetically heterogeneous tumors? Virchows Arch 449(4):455-461 (Pubitemid 44451320)
20. Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4): 704-715 (Pubitemid 351636299)
21. Arumugam T et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820-5828
22. Cheng GZ et al (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67(5):1979-1987 (Pubitemid 46424214)
23. Ansieau S et al (2008) Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14(1):79-89 (Pubitemid 351890463)
24. Buck E et al (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68(20):8322-8332
25. Thomson S et al (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25(8):843-854
26. Adam L et al (2009) MiR-200 expression regulates epithelial-tomesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15(16):5060-5072.
27. Buck E et al (2007) Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6(2):532-541 (Pubitemid 46332455)
28. Frederick BA et al (2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6(6):1683-1691 (Pubitemid 46954044)
29. Fuchs BC et al (2008) Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68(7):2391-2399 (Pubitemid 351521814)
30. Shrader M et al (2007) Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 6(1):277-285 (Pubitemid 46206692)
31. Thomson S et al (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65(20):9455-9462 (Pubitemid 41508014)
32. Witta SE et al (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66(2):944-950 (Pubitemid 43165962)
33. Yauch RL et al (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11(24 Pt 1):8686-8698 (Pubitemid 43005918)
34. Angelucci A et al (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13(1):197-210
35. Lo HW et al (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67(19): 9066-9076
36. Kim HJ et al (2007) Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 27(8):3165-3175
37. Brabletz T et al (2005) Opinion: Migrating cancer stem cells- an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744-749 (Pubitemid 41486367)
38. Moody SE et al (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8(3): 197-209 (Pubitemid 41317591)
39. Gossen M et al (1994) Inducible gene expression systems for higher eukaryotic cells. Curr Opin Biotechnol 5(5):516-520 (Pubitemid 24321420)
40. Petti F et al (2005) Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930. Mol Cancer Ther 4(8):1186-1197 (Pubitemid 41149566)
41. Thelemann A et al (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 4(4):356-376 (Pubitemid 40590556)
42. Ross PL et al (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3(12):1154-1169
43. Shilov IV et al (2007) The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 6(9):1638-1655 (Pubitemid 47506173)
44. Bradshaw RA et al (2006) Reporting protein identification data: The next generation of guidelines. Mol Cell Proteomics 5(5): 787-788 (Pubitemid 43792788)
45. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415-428 (Pubitemid 46809165)
46. Oltean S et al (2006) Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 103(38):14116-14121 (Pubitemid 44452989)
47. Dumont N et al (2008) Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 105(39):14867-14872
48. Dennis G Jr et al (2003) DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 4(5):P3
49. da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57
50. Andarawewa KL et al (2007) Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res 67(18):8662-8670 (Pubitemid 47439813)
51. Blick T et al (2010) Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 15(2):235-252
52. Carro MS et al (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279): 318-325
53. Choi YL et al (2010) LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 70(6):2296-2306
54. Coldren CD et al (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4(8):521-528 (Pubitemid 44341362)
55. Creighton CJ et al (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18): 7493-7501
56. De Craene B et al (2005) The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res 65(14):6237-6244 (Pubitemid 40994409)
57. Hennessy BT et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-tomesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-4124
58. Jorissen RN et al (2009) Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res 15(24):7642-7651
59. Joyce T et al (2009) A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis 26(6):569-587
60. Keshamouni VG et al (2009) Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J Proteome Res 8(1):35-47
61. Keshamouni VG et al (2006) Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/ invasive phenotype. J Proteome Res 5(5):1143-1154 (Pubitemid 43727792)
62. Lien HC et al (2007) Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 26(57):7859-7871 (Pubitemid 350261788)
63. Lim E et al (2010) Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 12(2):R21
64. Argast GM et al (2010) Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs 193(1-2):114-132
65. Vijayakumar S et al (2009) Phosphorylation of human DNA ligase I regulates its interaction with replication factor C and its participation in DNA replication and DNA repair. Mol Cell Biol 29(8):2042-2052
66. Birchmeier W, Weidner KM, Behrens J (1993) Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells. J Cell Sci Suppl 17:159-164 (Pubitemid 24041294)
67. Moreno-Bueno G, Portillo F, Cano A (2008) Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 27(55):6958-6969
68. Singh AB, Sharma A, Dhawan P (2010) Claudin family of proteins and cancer: an overview. J Oncol 541957
69. Harris TJ, Tepass U (2010) Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol 11(7):502-514
70. Yin T, Green KJ (2004) Regulation of desmosome assembly and adhesion. Semin Cell Dev Biol 15(6):665-677 (Pubitemid 39550246)
71. Li C et al (2004) Myristoylated Naked2 escorts transforming growth factor alpha to the basolateral plasma membrane of polarized epithelial cells. Proc Natl Acad Sci USA 101(15):5571-5576 (Pubitemid 38481197)
72. Maeda M, Johnson KR, Wheelock MJ (2005) Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 118(Pt 5):873-887 (Pubitemid 40484880)
73. Janji B et al (2006) Phosphorylation on Ser5 increases the F-actin-binding activity of L-plastin and promotes its targeting to sites of actin assembly in cells. J Cell Sci 119(Pt 9):1947-1960 (Pubitemid 43811019)
74. Florek M et al (2007) Prominin-2 is a cholesterol-binding protein associated with apical and basolateral plasmalemmal protrusions in polarized epithelial cells and released into urine. Cell Tissue Res 328(1):31-47 (Pubitemid 46411908)
75. Rubin C, Gur G, Yarden Y (2005) Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res 15(1):66-71 (Pubitemid 41653969)
76. Xu Y et al (2006) Oxidative inhibition of receptor-type proteintyrosine phosphatase kappa by ultraviolet irradiation activates epidermal growth factor receptor in human keratinocytes. J Biol Chem 281(37):27389-27397 (Pubitemid 44401766)
77. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39-51
78. Suman P et al (2009) Interleukin-11 increases invasiveness of JEG-3 choriocarcinoma cells by modulating STAT3 expression. J Reprod Immunol 82(1):1-11
79. Sullivan NJ et al (2009) Interleukin-6 induces an epithelialmesenchymal transition phenotype in human breast cancer cells. Oncogene 28(33):2940-2947
80. Gao SP et al (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117(12):3846-3856 (Pubitemid 350224094)
81. Yao Z et al (2010) TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107(35):15535-15540
82. Putoczki T, Ernst M (2010) More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 88(6):1109-1117
83. Sotiriou C et al (2001) Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 169(1):87-95 (Pubitemid 32532100)
84. Garlanda C et al (2007) Increased susceptibility to colitisassociated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res 67(13):6017-6021 (Pubitemid 47037479)
85. Hao Z et al (2008) Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 105(10):3939-3944 (Pubitemid 351723503)
86. Lee YJ et al (2010) Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res 70(3):948-956
87. Li Y et al (2009) Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28(39):3442-3455
88. Gjerdrum C et al (2010) Axl is an essential epithelial-tomesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 107(3):1124-1129
89. Rikova K et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190-1203 (Pubitemid 350235027)
90. Rajalingam K et al (2005) Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 7(8):837-843 (Pubitemid 41079057)
91. Zohn IE et al (2006) p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell 125(5):957-969 (Pubitemid 43810156)
92. Batlle E et al (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2(2):84-89
93. Aigner K et al (2007) The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26(49):6979-6988 (Pubitemid 350014612)
94. Spaderna S et al (2008) The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68(2):537-544 (Pubitemid 351380082)
95. Song Y, Washington MK, Crawford HC (2010) Loss of FOXA1/ 2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70(5):2115-2125
96. Yang Z et al (2005) Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res 65(8):3179-3184 (Pubitemid 40524599)
97. Chong C et al (2001) The mechanism of PAK activation. Autophosphorylation events in both regulatory and kinase domains control activity. J Biol Chem 276(20):17347-17353
98. de Hoog CL, Foster LJ, Mann M (2004) RNA and RNA binding proteins participate in early stages of cell spreading through spreading initiation centers. Cell 117(5):649-662 (Pubitemid 38692530)
99. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8(7):579-591
100. Sykiotis GP, Bohmann D (2010) Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal 3(112):re3
101. Radisky DC et al (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436(7047):123-127 (Pubitemid 40966197)
102. Cook PJ et al (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458(7238):591-596
103. Xiao A et al (2009) WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature 457(7225):57-62
104. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029-1033
105. St John MA et al (2009) Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. Clin Cancer Res 15(19):6018-6027.